A detailed history of Engineers Gate Manager LP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 11,575 shares of RARE stock, worth $506,406. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,575
Previous 14,364 19.42%
Holding current value
$506,406
Previous $590,000 8.81%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$40.21 - $59.36 $112,145 - $165,555
-2,789 Reduced 19.42%
11,575 $642,000
Q2 2024

Aug 14, 2024

SELL
$37.42 - $51.61 $2.45 Million - $3.38 Million
-65,505 Reduced 82.02%
14,364 $590,000
Q1 2024

May 15, 2024

BUY
$43.02 - $53.69 $3.05 Million - $3.81 Million
70,917 Added 792.19%
79,869 $3.73 Million
Q4 2023

Feb 14, 2024

SELL
$31.73 - $49.19 $273,004 - $423,230
-8,604 Reduced 49.01%
8,952 $428,000
Q3 2023

Nov 14, 2023

SELL
$34.92 - $46.66 $536,720 - $717,164
-15,370 Reduced 46.68%
17,556 $625,000
Q2 2023

Aug 14, 2023

BUY
$37.35 - $52.15 $629,459 - $878,883
16,853 Added 104.85%
32,926 $1.52 Million
Q1 2023

May 15, 2023

BUY
$36.99 - $48.71 $594,540 - $782,915
16,073 New
16,073 $644,000
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $1.43 Million - $2.37 Million
35,788 New
35,788 $1.48 Million
Q3 2021

Nov 15, 2021

SELL
$77.92 - $102.4 $1.66 Million - $2.18 Million
-21,316 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$92.19 - $115.71 $1.97 Million - $2.47 Million
21,316 New
21,316 $2.03 Million
Q1 2021

May 17, 2021

SELL
$106.9 - $167.73 $1.14 Million - $1.79 Million
-10,677 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$84.4 - $177.39 $901,138 - $1.89 Million
10,677 New
10,677 $1.48 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.06B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.